美国FDA和欧盟EMA启动仿制药申请检查合作
首页 > 资讯 > 美国FDA和欧盟EMA启动仿制药申请检查合作 出自识林
美国FDA和欧盟EMA启动仿制药申请检查合作
笔记 2013-12-21 FDA 美国FDA和欧盟EMA于12月18日公布一项共享仿制药申请生物等效性(bioequivalence, BE)研究检查信息的协议。“我们与欧盟和EMA的长期合作有助于更有效的分配检查资源,以应对药品研发全球化带来的挑战。” 美国FDA药品审评与研究中心主任Janet Woodcock博士指出,“通过提高仿制药申请检查流程的效率,将有助于患者获得更为安全有效的仿制药” 合作协议的要点包括:
识林-枫 2013-12-21 FDA and European Medicines Agency launch generic drug application inspections initiative The U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced the launch of a joint initiative to share information on inspections of bioequivalence studies submitted in support of generic drug approvals. This collaborative effort provides a mechanism to conduct joint facility inspections for generic drug applications submitted to both agencies. Studies submitted for generic drug applications must demonstrate scientifically that a generic drug is “bioequivalent”. These studies help demonstrate that the generic drug performs in the same manner as the brand name drug. The FDA and the regulatory authorities in the European Union (EU) inspect facilities that conduct these studies to ensure data submitted to the agencies are reliable. Taking part in this initiative are the EMA and the EU member states France, Germany, Italy, the Netherlands and the United Kingdom. "Our continued collaboration with the EMA and the EU enhances our ability to leverage inspection resources and helps us meet the challenges of increased globalization in drug development," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "By streamlining the inspection process for generic drug applications, we will help consumers gain access to safe and effective generic drugs." Key objectives of the initiative are to:
This initiative will be implemented using the confidentiality arrangements established among the European Commission, the EMA, interested EU member states and the FDA. This agreement includes an 18-month pilot phase and follows on the successful 2009 EMA-FDA Good Clinical Practices (GCP) Initiative, designed by the agencies to ensure that clinical trials data submitted in new drug applications in the United States and Europe are conducted ethically and are reliable. For more information: 原文请见 FDA and European Medicines Agency launch generic drug application inspections initiative |